4D Molecular Therapeutics GAAP EPS of -$0.98 misses by $0.36

2 hours ago 1

4D Molecular Therapeutics press release (NASDAQ:FDMT): Q2 GAAP EPS of -$0.98 misses by $0.36.
$417 million in cash, cash equivalents and marketable securities as of June 30, 2025, expected to fund planned operations into 2028

Recommended For You